Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | BLM | P54132 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | ARG1 | P05089 | 5/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.50 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.39 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.39 |
| ▸ | ARG2 | P78540 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2964302 | 1.00 | MEN1 (0.63) | MEN1BLMKMT2AARG1SLC1A2 | |
| SCHEMBL17943259 | 1.00 | MEN1 (0.63) | MEN1BLMKMT2AARG1SLC1A2 | |
| SCHEMBL3260294 | 1.00 | MEN1 (0.63) | MEN1BLMKMT2AARG1SLC1A2 | |
| SCHEMBL2964298 | 1.00 | MEN1 (0.63) | MEN1BLMKMT2AARG1SLC1A2 | |
| SCHEMBL12909421 | 1.00 | MEN1 (0.63) | MEN1BLMKMT2AARG1SLC1A2 | |
| Hydrochloric Acid SCHEMBL28578650 | 0.98 | MEN1 (0.61) | MEN1BLMKMT2AARG1SLC1A2 | |
| SCHEMBL18561419 | 0.91 | MEN1 (0.53) | MEN1BLMKMT2AARG1SLC1A2 | |
| SCHEMBL1364961 | 0.86 | — | — | |
| SCHEMBL114870 | 0.86 | — | — | |
| SCHEMBL2025245 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112851568-B | Synthetic method of 3-hydroxy-2-piperidinecarboxylic acid compound and hydrochloride thereof | 五邑大学 | 2022-06-24 | — | — | CN | claimed |
| CN-112851568-A | Synthetic method of 3-hydroxy-2-piperidinecarboxylic acid compound and hydrochloride thereof | 五邑大学 | 2021-05-28 | — | — | CN | claimed |
| EP-2957295-B1 | METHOD FOR TREATING ALZHEIMER'S DISEASE USING PHARMACOLOGICAL CHAPERONES TO INCREASE THE ACTIVITY OF GANGLIOSIDASES | AMICUS THERAPEUTICS INC (US) | 2017-08-02 | — | — | EP | claimed |
| US-20160213733-A1 | CHARACTERIZATION OF RICE | PHYTOQUEST LIMITED (GB) | 2016-07-28 | — | — | US | claimed |
| EP-3027185-A1 | CHARACTERIZATION OF RICE | Phytoquest Limited (GB) | 2016-06-08 | — | — | EP | claimed |
| US-9101662-B2 | Compositions with modulating agents | FOAMIX PHARMACEUTICALS LTD. (IL) | 2015-08-11 | — | — | US | claimed |
| EP-2490712-B1 | METHOD FOR TREATING ALZHEIMER'S DISEASE USING PHARMACOLOGICAL CHAPERONES TO INCREASE THE ACTIVITY OF GANGLIOSIDASES | AMICUS THERAPEUTICS INC (US) | 2015-07-08 | — | — | EP | claimed |
| WO-2015015186-A1 | CHARACTERIZATION OF RICE | PHYTOQUEST LIMITED (GB) | 2015-02-05 | — | — | WO | claimed |
| US-8795693-B2 | Compositions with modulating agents | FOAMIX LTD. (IL) | 2014-08-05 | — | — | US | claimed |
| EP-2097065-A2 | FOAMABLE WATERLESS COMPOSITIONS WITH MODULATING AGENTS | Foamix Ltd. (IL) | 2009-09-09 | — | — | EP | claimed |
| WO-2008152444-A2 | FOAMABLE WATERLESS COMPOSITIONS WITH MODULATING AGENTS | FOAMIX LTD. (US) | 2008-12-18 | — | — | WO | claimed |
| US-20080206159-A1 | Drug mixture contains solvents, nonionic surfactants, gelling agent, therapeutic active agent, liquefied or compressed gas propellant; pressurized dispenser; treating skin diseases, dermal and mucosal delivery; stable and non-irritating emulsions | FOAMIX LTD. (IL) | 2008-08-28 | — | — | US | claimed |
| WO-2026100698-A1 | L-GLUTAMATE OXIDASE, AND METHOD FOR PRODUCING α-KETOGLUTARIC ACID OR HYDROXYPIPECOLIC ACID | ＵＢＥ株式会社 | 2026-05-15 | — | — | WO | disclosed |
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | TEAM MEDICAL, LLC | 2025-09-18 | — | — | US | disclosed |
| US-20250179542-A1 | BIOCATALYSTS AND METHODS FOR HYDROXYLATION OF CHEMICAL COMPOUNDS | CODEXIS INC (US) | 2025-06-05 | — | — | US | disclosed |
| US-12286648-B2 | Engineered proline hydroxylase biocatalysts for hydroxylation of chemical compounds | CODEXIS, INC. (US) | 2025-04-29 | — | — | US | disclosed |
| US-20030055094-A1 | Bicyclic modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2003-03-20 | — | — | US | disclosed |
| US-6174858-B1 | CONJUGATE INCLUDING AN OLIGOPEPTIDE CAPABLE OF BEING PROTEOLYTICALLY CLEAVED BY THE ENZYMATIC ACTIVITY OF THE FREE PROSTATE SPECIFIC ANTIGEN | MERCK & CO., INC. | 2001-01-16 | — | — | US | disclosed |
| EP-1036093-A1 | CONJUGATES USEFUL IN THE TREATMENT OF PROSTATE CANCER | Merck & Co., Inc. (US) | 2000-09-20 | — | — | EP | disclosed |
| WO-1999028345-A1 | CONJUGATES USEFUL IN THE TREATMENT OF PROSTATE CANCER | MERCK & CO., INC. (US) | 1999-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080206159-A1 | Drug mixture contains solvents, nonionic surfactants, gelling agent, therapeutic active agent, liquefied or compressed gas propellant; pressurized dispenser; treating skin diseases, dermal and mucosal delivery; stable and non-irritating emulsions | CUTA, SLTM, SMO | MEN1 1332/4885BLM 3218/4885KMT2A 4642/4885 |
| US-20030055094-A1 | Bicyclic modulators of androgen receptor function | AR, NR5A1, ESRRA | MEN1 3920/4885BLM 3884/4885KMT2A 2827/4885 |
| US-20160213733-A1 | CHARACTERIZATION OF RICE | AGL, UGGT1, GYS2 | MEN1 3217/4885BLM 2642/4885KMT2A 3798/4885 |
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | SYNCRIP, SNRPA, RNASE1 | MEN1 3452/4885BLM 1193/4885KMT2A 2845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.